1.1Allyl ester on benzoate
The allyl ester keeps the aromatic carboxyl group masked during peptide coupling. A palladium catalyst and an allyl scavenger cleave the ester, and aqueous acidification gives the benzoic acid group.
Generated automatically. Not reviewed by a person. Not legal advice or an opinion.
Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
The allyl ester keeps the aromatic carboxyl group masked during peptide coupling. A palladium catalyst and an allyl scavenger cleave the ester, and aqueous acidification gives the benzoic acid group.
An aqueous workup removes acid and soluble ionic residues while the neutral intermediate partitions into an organic phase. Solvent exchange prepares that phase for the next transformation without isolating a salt.
A peptide building block bearing an N-ethyl group supplies the substituent at position 16. Coupling its secondary amine with an activated carboxyl group forms the tertiary amide, and a separate coupling closes the macrocycle.
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
The pinacol ester of 4-(methoxycarbonyl)phenylboronic acid replaces the free boronic acid on an equal aryl-mole basis. A stirred vessel combines the ester and macrocyclic aryl bromide in the aromatic solvent with a palladium catalyst and aqueous potassium carbonate. Agitation renews contact between the phases, and the aqueous base supports transfer of the aryl group from boron to palladium.
A temperature-controlled block holds twelve 2 mL reaction vials, each with a stir bar and a 0.50 mL working volume. Each vial contains 25 µmol of macrocyclic aryl bromide, and the aryl donor loads span 1.1, 1.3, and 1.5 mol per mole of aryl bromide, with four replicates at each load. All vials use the same catalyst and base loadings, solvent composition, and stirring setting. Matched samples taken at 30 and 60 minutes provide liquid chromatography measurements of conversion and impurity formation.
The batch reactor feeds a phase separator, a particulate filter, and a packed column containing thiol-functionalized silica. After the coupling, the separator removes the aqueous phase and the filter removes suspended solids from the organic stream. The organic stream passes through the column, where the immobilized thiol groups bind residual palladium. Inlet and outlet samples are analyzed by inductively coupled plasma mass spectrometry to measure palladium removal.
The coupling reactor feeds a phase separator and a jacketed vacuum evaporator fitted with a condenser and a distillate receiver. The separator sends the product-bearing organic phase to the evaporator, where reduced pressure removes the aromatic solvent while the protected macrocycle remains in the vessel. A metering pump adds ethyl acetate during evaporation to keep the concentrate stirrable. Gas chromatography of a vessel sample measures residual aromatic solvent before the solution transfers to the isolation vessel.
An automated sampling loop connects the stirred reactor to an at-line liquid chromatograph through a metering valve and a sample quench station. The sampler withdraws and dilutes aliquots at fixed intervals, and the chromatograph measures residual aryl bromide against a calibration curve. The controller turns off heating and starts jacket cooling after two consecutive measurements place the residual aryl bromide below the configured endpoint.
Acetonitrile carries the neutral protected macrocycle as a solution. Liquid chromatography measures the concentration before the solution is metered into an ester hydrolysis step.
The neutral protected macrocycle is dissolved in a mixture of tert-butanol and water and frozen. Sublimation under reduced pressure removes the solvent mixture and leaves a dry powder.
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
Particularly preferred are compounds of formula I selected from the group consisting of indole-1-carboxylic acid methyl ester, indole-1-carboxylic acid ethyl ester, indole-1-carboxylic acid isopropyl ester, indole-1-carboxylic acid allyl ester, 7-methyl-indole-1-carboxylic acid methyl ester and 5-methyl-indole-1-carboxylic acid methyl ester.A · US 7,632,956 B2 · ¶ 12
(11S,14S,17S)-14-(4-Amino-butyl)-11-(3-amino-propyl)-22-chloro-17-(1H-indol-3-ylmethyl)-16-methyl-2-thia-4,10,13,16,19-pentaaza-tricyclo[19.4.0.0*3,8*]pentacosa-1(25),3,5,7,21,23-hexaene-12,15,18-trione;B · US 2018/0362578 A1 · ¶ 283
An empty cell means only that no passage was reproduced there.
Unfortunately, methyl anthranilate leads to coloration under UV-irradiation.A · US 7,632,956 B2 · ¶ 3
Furthermore, in comparison to anthranilates, certain indole carbamates of the present invention have better substantivity on a substrate, such as a fabric or hair, when used in an aqueous medium.A · US 7,632,956 B2 · ¶ 4
The present invention provides compounds which exhibit activity against Acinetobacter baumannii, their manufacture, pharmaceutical compositions comprising them and their use as medicaments for the treatment of diseases and infections caused by Acinetobacter baumannii.B · US 2018/0362578 A1 · ¶ 2
Acinetobacter baumannii is a Gram-negative, aerobic, nonfermenting bacterium recognized over the last decades as an emergining pathogen with very limited treatment options.B · US 2018/0362578 A1 · ¶ 5
patent.fyi, US 2026/0356885 A1, claim 1, first published 2026-11-20T08:53:13-05:00, https://patent.fyi/US20260356885/, SHA-256 ec4e9f6cf366b1e6f7b294f5ef5af4390ee4cfd296153a14e2e84d48d1c08622